Evidence map›Paper›PMID 23867711›Full record

ArticleFungal genetics and biology : FG & B

Plasmids for increased efficiency of vector construction and genetic engineering in filamentous fungi.

Taylor J Schoberle, C Kim Nguyen-Coleman, Gregory S May

Abstract read
In one paragraph

Article in Fungal genetics and biology : FG & B. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. International journal of molecular sciences · 2019
    Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Taylor J SchoberleThe University of Texas Graduate School of Biomedical Sciences at Houston, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
C Kim Nguyen-Coleman
Gregory S May
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Molecular Genetics of AspergillosisR01AI051144 · NIAID · UNIVERSITY OF TEXAS MD ANDERSON CAN CTR · PI MAY, GREGORY S. · 2002 to 2005
$1.1M
Echinocandin Resistance in AspergillusR01AI074673 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MAY, GREGORY S. · 2009 to 2010
$770k
NCI NIH HHS CA016672NCI NIH HHS P30 CA016672NIAID NIH HHS AI051144NIAID NIH HHS AI074673NIAID NIH HHS R01 AI051144NIAID NIH HHS R01 AI074673
6 · The paper itself

Abstract

Fungal species are continuously being studied to not only understand disease in humans and plants but also to identify novel antibiotics and other metabolites of industrial importance. Genetic manipulations, such as gene deletion, gene complementation, and gene over-expression, are common techniques to investigate fungal gene functions. Although advances in transformation efficiency and promoter usage have improved genetic studies, some basic steps in vector construction are still laborious and time-consuming. Gateway cloning technology solves this problem by increasing the efficiency of vector construction through the use of λ phage integrase proteins and att recombination sites. We developed a series of Gateway-compatible vectors for use in genetic studies in a range of fungal species. They contain nutritional and drug-resistance markers and can be utilized to manipulate different filamentous fungal genomes.

Indexed as

Genetic EngineeringFungiGenetic VectorsGenome, FungalPlasmidsTransformation, GeneticFilamentous fungiGateway technologyGenetic engineeringRecombination

Identifiers

PMID23867711
PMCPMC3817716
OpenAlexW1969728717

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.